Patent ID: 8846763
Filing Date: 2014-09-30
Classification: A61K,A61P,C07C

Abstract:
1. A method for treating central nervous system (CNS) disorders selected from the group consisting of epilepsy, Parkinson's disease, Alzheimer's disease, depression, restless legs syndrome, pain and migraine which comprises the step of administering to a patient in need thereof an effective amount of (S)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide, (Ia) its R-enantiomer (I′a), their racemic mixture (Ia, I′a) or a pharmaceutically acceptable salt thereof, and, optionally, one or more additional active agents, wherein safinamide (Ia), its R-enantiomer (I′a), their racemic mixture (Ia, I′a) or a pharmaceutically acceptable salt thereof has a content of the impurity (S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide (IIa), its R-enantiomer (II'a), their racemic mixture (IIa, II'a), or a salt thereof with a pharmaceutically acceptable acid which is lower than 0.03% (by weight) and is obtained by a process characterized in that a Schiff base intermediate of formula (IIIa) its R-enantiomer or their racemic mixture (IIIa, III'a),